Table 2

Cytology, aberrant promoter hypermethylation, and LOH at 9p23 in nonmalignant BECs from lung cancer cases and controls

End pointBronchial epithelial sites (no. subjects positive at 1–4 sites)a
OneTwoThreeFour
CaseControlCaseControlCaseControlCaseControl
Cytologyb27/51 (54)22/41 (54)17/51 (33)8/41 (20)10/42 (25)1/36 (3)c1/24 (4)1/31 (3)
P16 methylation23/52 (44)18/41 (44)8/52 (14)6/41 (15)2/42 (5)1/36 (3)0/24 (0)0/31 (0)
DAP kinase methylation5/52 (10)d4/41 (10)d0/52 (0)0/41 (0)0/42 (0)0/36 (0)0/24 (0)0/31 (0)
9p23 LOH25/35 (71)19/26 (73)18/35 (51)8/26 (31)9/30 (30)5/21 (24)5/21 (23)1/13 (8)
  • a Summary data are presented as the total number of cases and controls who were positive per total sample population for cytology, methylation, or LOH at 9p23 in at least one, two, three, or four bronchial epithelial sites. Because only two sites were collected from some cases and controls, the number of persons who could be evaluated for positivity at three or four sites was fewer than the total sample size. Values in parentheses refer to the percentage of persons positive.

  • b Metaplasia (reactive) and mild dysplasia (atypia) were the predominant cytological abnormalities observed.

  • c P = 0.007 as compared with cases.

  • d P = 0.001 as compared with p16 methylation.